Fate Therapeutics director granted 87,900 options
Fate Therapeutics director Michael Stewart Lee received a grant of stock options as compensation for his board service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Fate Therapeutics director Michael Stewart Lee received a grant of stock options as compensation for his board service. The award covers 87,900 stock options to purchase common shares at an exercise price of $2.06 per share, expiring on June 12, 2036. The options vest in full on the earlier of June 12, 2027 or the company’s 2027 annual stockholders’ meeting, subject to his continued board service. The grant is held by Lee as a nominee for Redmile Group, LLC, which holds the economic and voting rights, and both Lee and Redmile parties disclaim beneficial ownership except to the extent of any pecuniary interest.
Insider Trade Summary
Grant/Award: 87,900 shares
Grant/Award
1 txn
Insider
Lee Michael Stewart
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 87,900 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 87,900 contracts (Direct)
Footnotes (4)
- F1. The stock option will vest in full and become exercisable upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date.
- F2. The stock option award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile. Mr. Lee disclaims beneficial ownership of the stock option award, if any, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F3. The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- F4. Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.
Key Figures
Stock options granted: 87,900 options
Exercise price: $2.06 per share
Expiration date: June 12, 2036
+3 more
6 metrics
Stock options granted
87,900 options
Grant to Michael Stewart Lee as board compensation
Exercise price
$2.06 per share
Strike price for the 87,900 stock options
Expiration date
June 12, 2036
Option term end date for the grant
Vesting date trigger
June 12, 2027 or 2027 annual meeting
Earlier of the two dates for full vesting
Shares underlying options
87,900 shares
Common stock underlying the granted options
Post-grant derivative holdings
87,900 options
Total options held following this reported transaction
Key Terms
Stock Option (Right to Buy), exercise price, vest in full and become exercisable, beneficial ownership, +2 more
6 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 2.0600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full and become exercisable financial
"The stock option will vest in full and become exercisable upon the earlier of"
beneficial ownership financial
"Mr. Lee disclaims beneficial ownership of the stock option award, if any"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
directors by deputization regulatory
"Redmile and Mr. Green are directors by deputization for purposes of Section 16"
Section 16 of the Securities Exchange Act of 1934 regulatory
"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Fate Therapeutics (FATE) report in this Form 4 filing?
Fate Therapeutics reported a grant of 87,900 stock options to director Michael Stewart Lee as board compensation. The options allow purchase of common stock at a $2.06 exercise price and represent a non-market, compensation-related award rather than an open-market trade.
What are the key terms of Michael Stewart Lee’s stock option grant at Fate Therapeutics (FATE)?
The grant covers 87,900 stock options with a $2.06 per-share exercise price, expiring June 12, 2036. The options vest in full on the earlier of June 12, 2027 or the 2027 annual stockholders’ meeting, contingent on Lee’s continued board service through that vesting date.
When do the new Fate Therapeutics (FATE) stock options granted to Michael Stewart Lee vest?
The options will vest in full on the earlier of June 12, 2027 or the date of Fate Therapeutics’ 2027 annual meeting of stockholders. Vesting is conditioned on Michael Stewart Lee continuing to serve on the company’s board of directors through the applicable vesting date.
Who ultimately benefits from the Fate Therapeutics (FATE) stock options granted to Michael Stewart Lee?
The options are held by Michael Stewart Lee as a nominee for Redmile Group, LLC and its affiliates. According to the filing, Redmile holds the economic and voting rights, while Lee, Redmile, and principal Jeremy Green each disclaim beneficial ownership except for any pecuniary interest.
Is the Fate Therapeutics (FATE) Form 4 transaction an open-market stock trade?
No, the Form 4 describes a compensation-related stock option grant, not an open-market purchase or sale. The transaction is coded as a grant or award (Code A), with options issued at a $2.06 exercise price and no cash price paid per option at the grant date.
Why is Redmile mentioned in the Fate Therapeutics (FATE) Form 4 for Michael Stewart Lee?
Michael Stewart Lee serves on the Fate Therapeutics board as a representative of Redmile and its affiliates. The filing states he holds the stock option award as a nominee for the sole benefit of Redmile, which has the economic and voting rights in respect of the option.
AI-generated analysis. How Rhea-AI works. Not financial advice.
